Piper Jaffray says ‘no good reason’ for Biohaven pullback

Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating on Biohaven after attending the company’s R&D day and hosting a fireside chat and investor dinner with company management during the 30th Annual Piper Jaffray Healthcare Conference. The analyst noted that Biohaven shares have experienced a significant pullback, for which he believes there was “no good fundamental reason.” Van Buren added that after this week, he has an even higher level on conviction in a “clean 12-month safety update and a successful Phase III ODT study… and therefore rimegepant’s $1B+ potential.”
https://thefly.com/landingPageNews.php?id=2830049